DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)

SHA:603233 Revenue

DaShenLin Pharmaceutical Group had revenue of 7.02B CNY in the quarter ending June 30, 2026, with 6.87% growth. This brings the company's total for the last twelve months to 27.97B, up 4.86% year-over-year. In the year 2025, DaShenLin Pharmaceutical Group had annual revenue of 27.50B with 3.80% growth. That makes DaShenLin Pharmaceutical Group the 2,977th largest company in the world by revenue and 349th in China.

• Revenue (ttm): 27.97B
• Revenue Growth: +4.86%
• P/S Ratio: 0.75
• Revenue / Employee: 679.87K
• Employees: 41,141
• Market Cap: 20.74B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Retail 22.35B 81.4%
• Franchise and Distribution 4.48B 16.3%
• Other Operations 635.01M 2.3%

Fiscal year ended Dec 31, 2025 See the full SHA:603233 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	27.50B	1.01B	3.80%
Dec 31, 2024	26.50B	1.97B	8.01%
Dec 31, 2023	24.53B	3.28B	15.45%
Dec 31, 2022	21.25B	4.49B	26.78%
Dec 31, 2021	16.76B	2.18B	14.92%

Data Source: S&P Global Market Intelligence Last updated: Aug 24, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 26, 2026

Data Sources Report a data error